MedTrace Logo

Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis

NCT00069186 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 107

Last updated 2005-06-24

No results posted yet for this study

Summary

The purpose of this study is to determine whether nine months of administration of creatine monohydrate results in an increase in muscle strength in patients with amyotrophic lateral sclerosis (ALS).

Conditions

  • Amyotrophic Lateral Sclerosis (ALS)

Interventions

DRUG

Creatine Monohydrate

Sponsors & Collaborators

  • The Avicena Group

    lead INDUSTRY

Principal Investigators

  • Rosenfeld Jeffrey, MD · Carolinas ALS Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Completion
2005-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00069186 on ClinicalTrials.gov